Updates on potential therapeutic targets in MSA

Abstract

Research into the genetic and molecular mechanisms underlying MSA has grown significantly in recent years. No neurorestorative treatments for MSA are available to date but there are many ongoing trials targeting α-syn pathways. Currently the standard of care in this condition remains symptom control. Levodopa is widely used, but while a small number of patients have some response to it, its benefit is short lasting and can worsen MSA symptoms, including OH and dyskinesia. First line treatment of OH remains midodrine, but new drugs such as atomoxetine have shown greater improvement in OH compared to midodrine in randomised trials.